Table 3 Characteristics of patients with grade 5 RP
No | Age (years)/Gender | Smoking history (pack-years) | Pathological types/Tumor stage | Treatment modality | Concurrent chemotherapy regimen | Induction chemotherapy regimen | Radiotherapy dose (Gy/fraction) | MLD (Gy) | Percentage of lung volume affected in subclinical ILD (%) | Time from treatment to grade 5 RP (months) |
|---|---|---|---|---|---|---|---|---|---|---|
1 | 59/Male | 20 | Adenocarcinoma/postoperative recurrence | CCRT | Cisplatin + pemetrexed | Cisplatin + gemcitabine | 60.0/30 | 12.12 | < 25 | 3.3 |
2 | 77/Male | 50 | Squamous cell carcinoma/IIIB | RT | None | Carboplatin + gemcitabine | 49.5/22 | 13.89 | ≥ 25 | 4.1 |
3 | 69/Male | 50 | Squamous cell carcinoma/IIIB | RT | None | Carboplatin + gemcitabine | 38.0/19 | 12.19 | ≥ 25 | 1.2 |
4 | 71/Male | 60 | SCLC/IIIA | CCRT | Cisplatin + etoposide | Cisplatin + etoposide | 60.0/30 | 12.65 | < 25 | 6.8 |
5 | 62/Male | 30 | Squamous cell carcinoma/postoperative recurrence | CCRT | Carboplatin + paclitaxel | None | 60.0/30 | 11.92 | < 25 | 3.0 |